Drug Profile
Research programme: cancer therapeutics - FujiFilm Holdings Corporation
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator FUJIFILM Holdings Corporation
- Developer FUJIFILM Holdings Corporation; Strategia Therapeutics
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 08 Apr 2015 Boston Strategic Corporation is now called Strategia Therapeutics